Additional Pharmacovigilance Study to Evaluate the Risks of Major Hemorrhage With the Administration of IMBRUVICA® (ibrutinib) First published 12/02/2019 Last updated 02/07/2024 EU PAS number:EUPAS27376 Study Finalised